Trial Profile
A Multicentre, Dose Finding, Phase II Study of CP-4055 in Combination With Sorafenib in Patients With Metastatic Malignant Melanoma.
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 13 Feb 2012
Price :
$35
*
At a glance
- Drugs Elacytarabine (Primary) ; Sorafenib
- Indications Malignant melanoma
- Focus Therapeutic Use
- 29 Jul 2008 Status changed from recruiting to suspended, according to a Clavis media release. The drug's safety profile was good under the current dosing regimen, but clinical activity was modest and only a limited number patients showed disease stabilisation.
- 23 Apr 2008 The trial is progressing according to plan, according to a Clavis Pharma media release.
- 13 Jul 2007 New trial record.